Table 2 Univariate and multivariate analysis for progression-free survival
Variables | PALBOCICLIB | RIBOCICLIB | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||
HR (95%) Cl | P value | HR (95%) Cl | P value | HR (95%) Cl | P value | HR(95%) Cl | P value | |
Age | 0,94 (0,91–0,97) | 0,001 | 0.95(0.90–1.00) | 0.053 | 0,99 (0.96–1.02) | 0.758 | ||
Number of metastatic sites | 3,8 (1.46–10.04) | 0.006 | 2.28 (0.64–8.09) | 0.201 | 0.95 (0.56–1.59) | 0.403 | ||
CDK inhibitor combination | 1.8 (0.91–3.67) | 0.089 | 1.26 (0.63–2.48) | 0.509 | ||||
ECOG PS | 0.215 (0.04–0.98) | 0.048 | 0.66 (0.09–4.95) | 0.694 | 0.67 (0.21–2.09) | 0.769 | ||
Pre/Post-menopause | 0.394 | 0.008 | 0.72 (0.25–2.03) | 0.537 | 0.71 (0.36–1.41) | 0.340 | ||
Visseral-nonvisseral disease | 0.58 (0,28–1.11) | 0.130 | 0.59 (0.29–1.18) | 0.135 | ||||
Dose reduction | 1.22 (0.62–2.37) | 0.550 | 1.21 (0.60–2.44) | 0.587 | ||||
CDK inhibitor interval | 1.92 (0.99–3.71) | 0.054 | 1.41 (0.68–2.89) | 0.361 | ||||
Concomitant use of PPIs | 5.60 (1.98–15.85) | < 0.001 | 7.85 (2.67–23.05) | < 0.001 | 2.90 (1.38–6.40) | 0.003 | 2.90 (1.38–6.40) | 0.003 |